Review





Similar Products

abciximab  (MedChemExpress)
93
MedChemExpress abciximab
Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
Abciximab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abciximab/pmc12478252-44-0-9?v=MedChemExpress
Average 93 stars, based on 1 article reviews
abciximab - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
abciximab  (Biocon Inc)
90
Biocon Inc abciximab
Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
Abciximab, supplied by Biocon Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abciximab/pm40525526-28-3-7?v=Biocon+Inc
Average 90 stars, based on 1 article reviews
abciximab - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
reopro® (abciximab) antibody  (Centocor Inc)
90
Centocor Inc reopro® (abciximab) antibody
Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
Reopro® (Abciximab) Antibody, supplied by Centocor Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abciximab/us12195475-352-32-37?v=Centocor+Inc
Average 90 stars, based on 1 article reviews
reopro® (abciximab) antibody - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
abciximab  (Eli Lilly)
86
Eli Lilly abciximab
Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
Abciximab, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abciximab/10__1155_slash_jocs_slash_3615306-93-3-5?v=Eli+Lilly
Average 86 stars, based on 1 article reviews
abciximab - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
abciximab reopro  (Eli Lilly)
90
Eli Lilly abciximab reopro
Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
Abciximab Reopro, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abciximab/pm39701440-16-10-12?v=Eli+Lilly
Average 90 stars, based on 1 article reviews
abciximab reopro - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
abciximab  (Mager Scientific)
90
Mager Scientific abciximab
Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
Abciximab, supplied by Mager Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abciximab/pmc11589161__41467_2024_54309_MOESM3_ESM-1321-16-22?v=Mager+Scientific
Average 90 stars, based on 1 article reviews
abciximab - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
monoclonal antibody abciximab reopro  (Eli Lilly)
90
Eli Lilly monoclonal antibody abciximab reopro
Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
Monoclonal Antibody Abciximab Reopro, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abciximab/pm39170431-50-1-7?v=Eli+Lilly
Average 90 stars, based on 1 article reviews
monoclonal antibody abciximab reopro - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
glycoprotein iib/iiia inhibitor abciximab reopro  (Eli Lilly)
90
Eli Lilly glycoprotein iib/iiia inhibitor abciximab reopro
Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 <t>(abciximab)</t> but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.
Glycoprotein Iib/Iiia Inhibitor Abciximab Reopro, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abciximab/pm38916492-101-6-11?v=Eli+Lilly
Average 90 stars, based on 1 article reviews
glycoprotein iib/iiia inhibitor abciximab reopro - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 (abciximab) but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.

Journal: Blood Vessels, Thrombosis & Hemostasis

Article Title: Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents

doi: 10.1016/j.bvth.2025.100096

Figure Lengend Snippet: Inhibition of thrombus formation by inhibitory antiplatelet antibody 7E3 (abciximab) but not by low dose aspirin in the Endo-chip laser-injury model. (A) Blood was incubated with vehicle, aspirin (9 μg/mL), or abciximab (20 μg/mL) for 1 hour at RT. Blood was then labeled with anti-CD41 antibody and antifibrin antibody, recalcified with CaCl 2 (10 mM), and then immediately perfused through the Endo-chip at 100 s –1 , followed by laser injury to the endothelial layer. Representative images of platelet (CD41, green) and fibrin (magenta) accumulation at the injury site at 10 minutes. (B) Kinetics of platelet (upper panel) and fibrin (lower panel) surface area coverage over time. (C) Platelet (upper panel) and fibrin (lower panel) AUC after treatment of blood with vehicle, aspirin, or abciximab. Mean ± SD, n = 3 to 5, 1-way analysis of variance with Dunnett’s multiple comparisons test. AUC, area under the curve.

Article Snippet: Abciximab (anti-αIIbβ3 inhibitory antibody, clone C7E3) was purchased from MedChemExpress LLC (Monmouth Junction, NJ).

Techniques: Inhibition, Incubation, Labeling